Skip to content

effect of plantago ovata on Dry eye

study of the effect of product of plantago ovata on Dry eye syndrome

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
IRCT
Registry ID
IRCT2015032621540N1
Enrollment
68
Registered
2015-05-05
Start date
2015-04-21
Completion date
Unknown
Last updated
2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dry eye syndrom. Other disorders of lacrimal gland

Interventions

Intervention 1: intervention : tear drop(15ml) contain of plantago ovata husk mucilage(1 gr/100ml). Intervention time:4 times a day, every time one drop for 6 weeks. Intervention 2: control: tear d
Treatment - Drugs
Placebo
intervention : tear drop(15ml) contain of plantago ovata husk mucilage(1 gr/100ml). Intervention time:4 times a day, every time one drop for 6 weeks
control: tear drop(15ml) contain of distilled water. Intervention time:4 times a day, every time one drop for 6 weeks

Sponsors

Vice Chancellor for research shahed univresityof Medical Science and Vice Chancellor for researchTeh
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Inclusion criteria: foreign body sensation in blinking or dryness in eye,lack of active infection of the eye,no active ocular allergy, no evidence of lid deformity or abnormal lid movement disorder, no refractive surgery,no pregnancy or lactation,no abnormal nasolacrimal drainage, no evidence of thyroid eye disease or graft-versus-host disease;no evidence of lid deformity or abnormal lid movement disorder;any history of eye burning;no history of pterygium exclusion criteria: active infection of the eye during the study, active ocular allergy during the study; if they initiated or altered the dose of chronic systemic medication known to affect tear production within 30 days of testing; if they did not wish to participate in the study or could not cooperate with the collection of tear samples.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

MeasureTime frame
Trear osmolarity. Timepoint: Baseline,6 weeks after starting the medication. Method of measurement: tear osmolarity maesurment whith osmolarity device-miliosmol /lit.;Foreign body sensation, photophobia, blur vision, Burning. Timepoint: Baseline,6 weeks after starting the medication. Method of measurement: Filling OSDI questionnaire.;Tear Break Up time. Timepoint: Baseline,6 weeks after starting the medication. Method of measurement: The time that takes for the first dry spot to appear following blinking whith keratogragh device-second.;Tear secretion. Timepoint: Baseline,6 weeks after starting the medication. Method of measurement: Schirmer test- Wetting of the filter paper after 5 minutes.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNada Haji Ali Nili

Shahed University of Medical Sciences

nili.neda@yahoo.com; n.nili@shahed.ac.ir+98 21 5567 8943

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026